Expand all sections

Tislelizumab

Tevimbra

Extended indication Extension of indication to include first-line treatment of adult patients with extensive-stage Small
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information